Assessment of nicotine delivery and uptake in users of various tobacco/nicotine products

[Display omitted] •Nicotine uptake doses from various products show a large overlap between each other.•Combustible cigarettes and oral tobacco products are at the high end of the nicotine uptake doses.•Simple models for daily amounts of nicotine intake can predict the nicotine doses for most produc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current research in toxicology 2022-01, Vol.3, p.100067, Article 100067
Hauptverfasser: Scherer, Gerhard, Mütze, Janina, Pluym, Nikola, Scherer, Max
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Nicotine uptake doses from various products show a large overlap between each other.•Combustible cigarettes and oral tobacco products are at the high end of the nicotine uptake doses.•Simple models for daily amounts of nicotine intake can predict the nicotine doses for most product users.•Larger deviations were observed for smokers and users of heated tobacco products.•The most probable reason for these deviations are differences in parameters for puffing and inhalation and actual behavior of the users. Today various tobacco and nicotine products are available, many of them can be regarded as potentially risk-reduced products when compared to the most frequently used product, combustible cigarettes (CCs). A commonality of these products is that they deliver nicotine, although in quite different amounts and uptake routes, the most common of which are inhalation through the lung and absorption through the oral mucosa. Product-specific nicotine delivery as well as the subject-related use patterns are important factors which determine the pharmacokinetics and achieved internal dose levels of the alkaloid. The latter two parameters are highly relevant for the long-term product loyalty and, consequently, for the implicated health risks, since the risk-reduced products will replace CCs in the long-term only when users will experience a similar level of satisfaction. We measured nicotine and its major metabolites in plasma, saliva and urine samples collected in a controlled clinical study with habitual users (10 per group) of CCs, electronic cigarettes (ECs), heated tobacco products (HTP), oral tobacco (OT), and nicotine replacement therapy (NRT). Non-users (NU) of any tobacco/nicotine products served as (negative) control group. Moderate to strong correlations were observed between the daily consumption and the urinary nicotine equivalents (comprising nicotine and its 10 major metabolites, Nic + 10) or plasma and saliva cotinine concentrations. The average daily nicotine dose as measured by the urinary excretion of Nic + 10 (reflecting approximately 95 % of the absorbed nicotine) amounted to 17 and 22 mg/24 h for smokers (CC) and OT users, respectively, while it was in the range of 6–12 mg/24 h for users of ECs, HTP and NRT products, with high inter-individual variations in each user group. The individual daily nicotine intake, which was calculated by applying product-specific models, showed none to good agreement with the corresponding interna
ISSN:2666-027X
2666-027X
DOI:10.1016/j.crtox.2022.100067